
The study assessed the accuracy of administrative claims data in identifying clinical endpoints from the Evolut Low-Risk Trial. Claims data successfully identified deaths, disabling strokes (sensitivity 68.8%, specificity 99.0%), and pacemaker placements (sensitivity 85.2%, specificity 98.4%) but showed more modest accuracy for myocardial infarction and vascular complications. Claims data replicated trial findings for the primary endpoint, supporting its use in postmarket surveillance for transcatheter aortic valve replacement.
Like
Save
Share